series-c-plus
Stage
2
Investors
About
Pangea Bio is a clinical-stage biotechnology company developing therapeutics that promote neuroplasticity to treat central nervous system disorders. Its lead candidate OT-003 activates the TrkB receptor pathway and has received Clinical Trial Authorization, and the company is advancing a pipeline of next-generation TrkB activators.
Explore Pangea Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.